Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

PARP1 trapping by PARP inhibitors drives cytotoxicity both in cancer cells and healthy bone marrow.

Hopkins TA, Ainsworth WB, Ellis PA, Donawho CK, DiGiammarino EL, Panchal SC, Abraham VC, Algire MA, Shi Y, Olson AM, Johnson EF, Wilsbacher JL, Maag D.

Mol Cancer Res. 2018 Nov 14. pii: molcanres.0138.2018. doi: 10.1158/1541-7786.MCR-18-0138. [Epub ahead of print]

PMID:
30429212
2.

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Kluge AF, Patane MA, Van Drie JH, Wang C, McElligott D, Kesicki EA, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD.

Nature. 2018 Jun;558(7710):E1. doi: 10.1038/s41586-018-0111-5.

PMID:
29769713
3.

ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models.

Li Y, Hickson JA, Ambrosi DJ, Haasch DL, Foster-Duke KD, Eaton LJ, DiGiammarino EL, Panchal SC, Jiang F, Mudd SR, Zhang C, Akella SS, Gao W, Ralston SL, Naumovski L, Gu J, Morgan-Lappe SE.

Mol Cancer Ther. 2018 May;17(5):1039-1050. doi: 10.1158/1535-7163.MCT-17-0800. Epub 2018 Mar 28.

PMID:
29592882
4.

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Van Drie JH, McElligott D, Kesicki E, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD.

Nature. 2017 Oct 5;550(7674):128-132. doi: 10.1038/nature24028. Epub 2017 Sep 27. Erratum in: Nature. 2018 May 16;:.

5.

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.

Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, Panchal SC, Wilsbacher JL, Gao W, Olson AM, Stolarik DF, Osterling DJ, Johnson EF, Maag D.

Mol Cancer Res. 2015 Nov;13(11):1465-77. doi: 10.1158/1541-7786.MCR-15-0191-T. Epub 2015 Jul 27.

6.

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.

Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM.

Mol Cancer Ther. 2015 May;14(5):1141-51. doi: 10.1158/1535-7163.MCT-14-0820. Epub 2015 Mar 2.

7.

Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design.

Digiammarino EL, Harlan JE, Walter KA, Ladror US, Edalji RP, Hutchins CW, Lake MR, Greischar AJ, Liu J, Ghayur T, Jakob CG.

MAbs. 2011 Sep-Oct;3(5):487-94. doi: 10.4161/mabs.3.5.16326. Epub 2011 Sep 1.

8.

Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant.

Lee AS, Galea C, DiGiammarino EL, Jun B, Murti G, Ribeiro RC, Zambetti G, Schultz CP, Kriwacki RW.

J Mol Biol. 2003 Mar 28;327(3):699-709.

PMID:
12634062
9.

Purification, crystallization and preliminary X-ray analysis of Caenorhabditis elegans ubiquitin-conjugation enzyme M7.1.

Gavira J JA, Claxton DP, Wang JH, Toh D, Meehan EJ, DiGiammarino EL.

Acta Crystallogr D Biol Crystallogr. 2003 Mar;59(Pt 3):544-6. Epub 2003 Feb 21.

PMID:
12595721
10.

A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer.

DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW.

Nat Struct Biol. 2002 Jan;9(1):12-6.

PMID:
11753428
11.

Defining the molecular basis of Arf and Hdm2 interactions.

Bothner B, Lewis WS, DiGiammarino EL, Weber JD, Bothner SJ, Kriwacki RW.

J Mol Biol. 2001 Nov 23;314(2):263-77.

PMID:
11718560
12.

Cloning, overexpression, and purification of aminoglycoside antibiotic nucleotidyltransferase (2'')-Ia: conformational studies with bound substrates.

Ekman DR, DiGiammarino EL, Wright E, Witter ED, Serpersu EH.

Biochemistry. 2001 Jun 19;40(24):7017-24.

PMID:
11401545
13.

Solution structure of the p53 regulatory domain of the p19Arf tumor suppressor protein.

DiGiammarino EL, Filippov I, Weber JD, Bothner B, Kriwacki RW.

Biochemistry. 2001 Feb 27;40(8):2379-86.

PMID:
11327858
14.

Conformations of antibiotics in active sites of aminoglycoside-detoxifying enzymes.

Serpersu EH, Cox JR, DiGiammarino EL, Mohler ML, Ekman DR, Akal-Strader A, Owston M.

Cell Biochem Biophys. 2000;33(3):309-21. Review. No abstract available.

PMID:
11325048
15.

Aminoglycoside antibiotics bound to aminoglycoside-detoxifying enzymes and RNA adopt similar conformations.

Cox JR, Ekman DR, DiGiammarino EL, Akal-Strader A, Serpersu EH.

Cell Biochem Biophys. 2000;33(3):297-308.

PMID:
11325047
16.

Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex.

Weber JD, Kuo ML, Bothner B, DiGiammarino EL, Kriwacki RW, Roussel MF, Sherr CJ.

Mol Cell Biol. 2000 Apr;20(7):2517-28.

Supplemental Content

Loading ...
Support Center